Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults

Shiran Leib, Bella Bielorai, Helly Vernitsky, Yarden Aharony-Tevet, Amos Toren, Elad Jacoby*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The presence of leukocytes in the cerebral spinal fluid (CSF) of patients with acute lymphoblastic leukemia may indicate a relapse in the central nervous system. CD19-directed immunotherapy may increase the blood-brain barrier permeability, leading to neurologic toxicity and infiltrate the CNS. We studied the CSF cell and protein content in 71 consecutive patients who received either CD19 chimeric antigen receptor T cells or blinatumomab. Responding patients had an incidence of 66% and 61% of pleocytosis following blinatumomab or chimeric antigen receptor T cells, respectively. CSF parameters did not correlate with toxicity or prior CNS disease. Routine CSF flow cytometry following immunotherapy to distinguish T-cell infiltration from CNS relapse should be considered.

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume46
Issue number1
DOIs
StatePublished - 1 Jan 2024

Keywords

  • CAR-T cells
  • acute lymphoblastic leukemia
  • blinatumomab
  • cerebral spinal fluid
  • tisagenlecleucel

Fingerprint

Dive into the research topics of 'Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults'. Together they form a unique fingerprint.

Cite this